KORSERDU^® monotherapy is indicated for the treatment of postmenopausal women, and men, with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer with an ESR1 mutation who have progressed following at least one line of endocrine therapy. 

Product: KORSERDU^®

Summary of Product Characteristics (SmPC): Great Britain SmPC^* | Northern Ireland SmPC^*

Patient Information Leaflet (PIL): Great Britain PIL^* 

*Please note: Menarini Stemline^® UK accepts no liability for external links.

NEXPOVIO^® is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. 

Product: NEXPOVIO^®

Summary of Product Characteristics (SmPC): Great Britain SmPC^* | Northern Ireland SmPC^*

Patient Information Leaflet (PIL): Great Britain PIL^* | Northern Ireland PIL^*

*Please note: Menarini Stemline^® UK accepts no liability for external links.